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Abstract
Purpose—Colorectal cancer remains the second leading cause of cancer deaths in the U.S. 
despite being eminently preventable by colonoscopy via removal of premalignant adenomas. In 
order to more effectively reduce colorectal cancer mortality, improved screening paradigms are 
needed. Our group pioneered the use of low coherence enhanced backscattering (LEBS) 
spectroscopy to detect the presence of adenomas throughout the colon via optical interrogation of 
the rectal mucosa. In a previous ex-vivo biopsy study of 219 patients, LEBS demonstrated 
excellent diagnostic potential with 89.5% accuracy for advanced adenomas. The objective of the 
current cross-sectional study is to assess the viability of rectal LEBS in-vivo.
Experimental Design—Measurements from 619 patients were taken using a minimally 
invasive 3.4 mm diameter LEBS probe introduced into the rectum via anoscope or direct insertion, 
requiring ~1 minute from probe insertion to withdrawal. The diagnostic LEBS marker was formed 
as a logistic regression of the optical reduced scattering coefficient  and mass density 
distribution factor D.
Results—The rectal LEBS marker was significantly altered in patients harboring advanced 
adenomas and multiple non-advanced adenomas throughout the colon. Blinded and cross-
Senior Corresponding Author: Hemant K. Roy MD, Professor of Medicine, Boston University Medical, 650 Albany Street, Suite 
526, Boston MA 02118, Phone: 847-570-3115, Fax: 847-733-5041, hkroy@bu.edu. 
Disclosures: Drs. Roy, Goldberg and Backman are co-founders/share-holders of American BioOptics LLC. Bradley Gould is a share-
holder of American BioOptics LLC. The remaining authors declare no conflicts of interest.
HHS Public Access
Author manuscript
Clin Cancer Res. Author manuscript; available in PMC 2016 October 01.
Published in final edited form as:
Clin Cancer Res. 2015 October 1; 21(19): 4347–4355. doi:10.1158/1078-0432.CCR-15-0136.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
validated test performance characteristics showed 88% sensitivity to advanced adenomas, 71% 
sensitivity to multiple non-advanced adenomas, and 72% specificity in the validation set.
Conclusions—We demonstrate the viability of in-vivo LEBS measurement of histologically 
normal rectal mucosa to predict the presence of clinically relevant adenomas throughout the colon. 
The current work represents the next step in the development of rectal LEBS as a tool for 
colorectal cancer risk stratification.
Keywords
Colorectal cancer; Field carcinogenesis; risk stratification; optical spectroscopy
Introduction
The ~35% decline in colorectal cancer (CRC) incidence rate since the mid-1980's is a 
testament to the huge success of colon cancer screening within the United States (1). In 
more recent years, much of this decline has been attributed to the increased uptake of the 
now “gold standard” colonoscopy, which has the ability to not only identify, but also to treat 
premalignant lesions through direct removal (2). Despite this proven capability, a number of 
sizeable disadvantages including high cost, limited endoscopist resources, patient 
discomfort, and the potential for procedural complications make colonoscopy an imperfect 
method for use in population-wide screening. Given that CRC remains the second leading 
cause of cancer death in the United States (~50,000 in 2014), improved screening paradigms 
are therefore still welcome (1).
In order to further reduce CRC mortality, a two-step paradigm shift in screening has often 
been proposed. Under this approach, patients within the asymptomatic population would 
first undergo a minimally invasive pre-screen to identify individuals at highest risk of 
developing CRC (i.e., patients harboring premalignant lesions). These high-risk individuals 
would then proceed to a follow-up colonoscopy for removal of all precancerous adenomas. 
A screening program of this kind could simultaneously optimize patient compliance and 
resource allocation in order to more effectively protect against the development of fatal 
CRC. Moreover, evidence of the effectiveness of such an approach is demonstrated in the 
tremendously successful Pap test – colposcopy screening paradigm for cervical cancer.
To ensure maximum efficacy as well as patient compliance, the pre-screening technique 
would need to be highly accurate at detecting premalignant lesions throughout the colon, 
pose a minimal amount of patient discomfort/harm, and have the ability to be carried out in 
the primary care setting or via at-home tests. Unfortunately, alternative imaging-based 
screening techniques such as flexible sigmoidoscopy and virtual colonoscopy cannot meet 
all of these stringent requirements (3). Another option that overcomes some of the 
limitations of imaging-based techniques is to implement less-invasive fecal tests. Given the 
low prevalence of CRC in the general screening population (~0.7% (4)) and that 
colonoscopy already possesses the ability to accurately detect and remove precancerous 
adenomas throughout the colon, the primary mandate of any CRC screening paradigm must 
be to identify patients with precancerous lesions (as recommended by the American Cancer 
Society, the US Multi Society Task Force on Colorectal Cancer, and the American College 
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of Radiology) (5). Yet all currently available fecal tests exhibit a lack of sensitivity to such 
treatable lesions. For example, while fecal occult blood test (FOBT), fecal immunochemical 
test (FIT), and stool DNA test (sDNA) have demonstrated excellent sensitivity to cancerous 
lesions, they provide low test sensitivity to precancerous advanced adenomas (10.8%, 
29.5%, and 42.4% sensitivity for FOBT (6, 7), FIT (7), and sDNA (4) respectively).
In an effort to improve upon existing screening tests, our multidisciplinary group focuses on 
identifying high-risk patients through application of the well-established concept of field 
carcinogenesis (8-14). Field carcinogenesis is the very initial stage of cancer progression in 
which a number of genetic/epigenetic mutations (e.g., DNA methylation (9), histone 
modifications (15), and altered cytoskeletal mediators of chromosomal stability (16)) spread 
diffusely throughout an organ due to common environmental insult and genetic composition 
(17). The resulting structural correlates of such mutations are subtle intracellular and 
extracellular alterations occurring at ultra-structural length-scales (i.e., < ~300 nm) (18). 
Taken together, the combined contribution from these mutational and structural alterations 
compose a fertile ‘field of injury’ from which focal arise via stochastic mutational events 
such as mutation of key oncogenes (e.g., KRas) and tumor suppressor genes (e.g., p53, 
adenomatous polyposis coli APC) (17). In clinical practice, field carcinogenesis provides the 
basis upon which flexible sigmoidoscopy is able to predict synchronous proximal neoplasia 
through inspection of the distal colon (17, 19). Moreover, our group has previously applied 
field carcinogenesis to optically detect colorectal adenomas throughout the colon via rectal 
measurements (17, 20-26).
Since the ultra-structural alterations occurring in field carcinogenesis are by definition 
smaller than the resolution limit of optical microscopy, the mucosa appears histologically 
normal under conventional endoscopy/histology. Our group therefore invented a novel 
optical spectroscopy technique known as low-coherence enhanced backscattering (LEBS) 
capable of selectively targeting the subtle ultra-structural changes occurring in colon field 
carcinogenesis (22, 27-29). In a previous ex-vivo LEBS study of rectal biopsies, our group 
confirmed the presence of ultra-structural alterations occurring at depths within the first 
400-600 μm of colonic mucosa (22). Moreover, we demonstrated that these optical changes 
contained excellent diagnostic potential with an overall accuracy of 89.5% for advanced 
adenomas (21). In order to translate these findings into the clinic for in-vivo application, we 
developed a minimally invasive 3.4 mm diameter fiber-optic LEBS probe optimized for 
detecting the previously observed changes (30). We therefore hypothesize that the changes 
previously measured ex-vivo should also be detectable in-vivo. In this paper, we determine 
the feasibility of in-vivo LEBS measurement of histologically normal rectal mucosa to 
predict the presence of precancerous adenomas throughout the colon on a cross-sectional 
study of 619 subjects.
Methods
Participants and acquisition of clinical data
This cross-sectional study was approved by the institutional review boards at NorthShore 
University HealthSystem, Indiana University School of Medicine, and the University of 
Chicago Medical Center. Patients were eligible for recruitment into the study if they were 
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already scheduled for population-based colonoscopy screening or surveillance as 
recommended by their general practitioner or gastroenterologist. 728 asymptomatic patients 
that were free of cancer were recruited into the study after providing written informed 
consent. 619 of these patients had completed data work-ups from an endoscopic findings 
report, a pathology report, a demographic information survey, and met the criteria for robust 
LEBS measurements discussed below. 602 of these patients were recruited for the main 
study, while the remaining 17 were recruited for a separate pilot study to assess the 
feasibility of performing LEBS in patients without colon preparation (further details found 
below).
All measurements were acquired through the point-of-care instrument shown in Fig. 1A 
(assembled by Tricor Systems, Elgin, IL). Following the withdrawal phase of colonoscopy, 
the 3.4 mm diameter LEBS probe was introduced into the rectal vault via direct insertion or 
anoscope. The endoscopist then took 10 readings from random locations within the rectum, 
applying gentle contact with the tissue surface. Each reading took less than 0.5 seconds and 
recorded the backscattered light intensity collected at 3 angles as shown in Fig. 1B. The 
entire procedure from probe insertion to extraction typically took less than 1 minute. 
Measurements were acquired by trained endoscopists and the final data analysis was 
performed in post-processing by the investigators using automated data analysis algorithms. 
At the time of data acquisition, endoscopists were blinded to the pathology findings of 
polyps retrieved during the preceding colonoscopy. 4 distinct endoscopists were used in this 
study. Histopathology reports were prepared by each study site with no centralized 
pathological review being performed.
In order to ensure the maximum level of patient compliance, LEBS will need to be 
performed in patients not subjected to colon preparation. To that end, a pilot study of 17 
patients were asked to undergo LEBS measurement at a date prior to colonoscopy in which 
they were not required to follow any preparation regimen (e.g., no bowel purge, dietary 
restrictions, etc.). The follow-up screening colonoscopy was then performed according to 
standard protocols within one month of the initial LEBS measurement.
For diagnostic purposes patients were classified into four categories: no dysplasia (control), 
1 or 2 non-advanced adenomas with size ≤ 9 mm, multiple (3 or more) non-advanced 
adenomas, and advanced adenomas (size ≥ 10 mm, ≥25% villous features, or high grade 
dysplasia). Due to their clinical relevance to CRC progression, the primary endpoint of our 
study was the identification of advanced adenomas. Adenoma size was specified as the 
largest polyp dimension reported on either the colonoscopy findings or pathology report. 
Polyp histomorphology (e.g., hyperplastic, adenomatous, and/or serrated) was determined 
based on pathology findings. We note that serrated histomorphology had no significant 
effect on our LEBS measurements – thus adenomas were grouped based solely on the 
criteria above. Diagnostic categorization was performed at Northwestern University with 
disagreements resolved by a consensus of at least two senior investigators.
LEBS fiber optic probe instrumentation and biomarkers
The principles behind the fiber-optic LEBS probe shown in Fig. 1C have previously been 
described in other publications (30, 31). In short, the LEBS probe (assembled by OFS, 
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Avon, CT; schematic in Fig. 1D) consists of 4 optical fibers terminated in a rigid housing 
that aligns the fibers into a linear array (see inset of Fig. 1D). One of the central fibers 
delivers white light illumination from a xenon lamp onto the tissue surface (< 1 mW 
delivered to tissue), while the remaining fibers collect backscattered light at 3 angles (−0.6°, 
+0.6° & +1.12° relative to the incident direction). The backscattered light is collected by a 
spectrometer-based system designed to collect visible light between 500 and 700 nm. In 
order to control the spatial coherence (Lsc) of the illumination and thereby limit the tissue 
depths that are interrogated, the illumination fiber core diameter is set to 50 μm and a 9 mm 
glass rod separates the fiber array from the tissue surface. This configuration results in Lsc = 
27 μm at 700 nm illumination corresponding to superficial penetration depths between 
~100-150 μm (30, 32).
LEBS analysis of tissue ultra-structure
A full description of the optical quantification of tissue ultra-structure can be found in other 
publications (22, 29, 33). Here, we briefly review the basic aspects that are pertinent for the 
current study.
Colon mucosa is composed of a wide variety of arbitrarily shaped structures ranging in size 
from tens of nanometers (e.g., cell membranes, histones, and cytoskeleton) to hundreds of 
nanometers and microns (e.g., mitochondria, nuclei, and collagen fibers) to hundreds of 
microns (e.g., colon crypts) in size. In order to quantify the spatial organization of such 
heterogeneous structures, we employ two bulk property parameters: the variance of mass 
density  and the mass density distribution factor D. Through application of scattering 
theory, LEBS can directly measure D and indirectly measure  using the reduced 
scattering coefficient  as a proxy (i.e., ) (34, 35).
Data processing and statistical analysis
All data processing and statistical analysis was performed using MATLAB version R2013A. 
Furthermore, the analysis included in the current work was performed at a time point after 
all training and validation data had been collected in the clinic.
The optical properties D and  are calculated using relationships derived in other 
publications (34, 35). D is calculated by fitting the power-law decay of diffusely scattered 
light intensity (measured as the spectrum of light collected at +1.12° - see Fig. 1B) as a 
function of wavelength: I(λ) ∝ λD–4. To calculate , we make the assumption that the 
anisotropy factor g = 0.9 in colonic mucosa (36). We then employ empirical relations 
derived using Monte Carlo simulation to calculate 
 (35), where E' is the average of 
the intensities measured at −0.6° and +0.6° minus the intensity at +1.12° (30, 35). Before 
applying these equations, the value of E' was first multiplied by a constant calibration factor 
of 0.31 to achieve agreement between experiment and Monte Carlo simulation.
Various data exclusion criteria were implemented to guarantee data robustness. First, we 
removed all measurements that resulted in E' < 0. Physically speaking E' must be greater 
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than 0, thus negative E' are indicative of aberrant measurements (e.g., poor probe contact 
pressure, regions of poor colon prep, or damaged tissue). We then excluded patients with 
values of D that were determined to be unphysical for rectal mucosa (e.g., D >6). Next, we 
removed individual measurements of E' and D whose values were outside of the range[Q1 
−1.5(Q3 −Q1),Q3 +1.5(Q3 −Q1)], where Q1 and Q3 are the 25th and 75th percentiles, 
respectively. After applying these criteria and provided that there was a minimum of 3 
usable measurements, the remaining measurements were averaged together to arrive at a 
final average patient measurement. We subsequently applied this same criterion to remove 
entire patients with abnormally high or low marker readings relative to their peers. In total, 
93 subjects were removed due to non-robust measurement.
In order to generate a single diagnostic biomarker (termed the LEBS marker) we combined 
D and  using multivariate logistic regression. To ensure the robustness of the LEBS 
marker prediction rule, we chronologically separated the first 80% of our dataset into a 
training set (N=476) and the final 20% into a blinded validation set (N=126). The prediction 
rule was then optimized between healthy controls and patients harboring advanced 
adenomas:
(1)
where an are coefficients assigned using the function ‘mnrfit’ applied to patients in the 
training set. The optimal LEBS marker threshold (threshold = −2.35) was then determined 
by maximizing the sensitivity and specificity of the training set (i.e., finding the point closest 
to sensitivity=specificity=1.0). Applying the logistic regression coefficients and LEBS 
marker threshold value to the validation set, we calculated the sensitivity, specificity, and 
the overall accuracy of the test by generating the receiver operating characteristic (ROC) 
curve using the function ‘perfcurve’. 95% confidence intervals on the sensitivity and 
specificity were calculated using the binomial proportion confidence interval, while for the 
overall accuracy they were calculated according to equations by Hanley and McNeil (37). 
Investigation into the contribution from confounding factors (e.g., age, race, smoking/
alcohol status, and personal and family history of adenomas/cancer) was evaluated by 
performing an analysis of covariance (ANCOVA) test using the function ‘anovan’.
Results
Patient Characteristics
Figure 2 diagrams the various patient groupings used in the current study. LEBS readings 
from 619 patients (age 58.4 ± 11.0 years; 60.0% female; 83.8% Caucasian) were included in 
our analysis. These 619 patients were separated into the main study of 602 ‘prepped’ 
patients with standard colon preparation and a pilot study of 17 ‘unprepped’ patients without 
colon preparation. In order to ensure the robustness of our unprepped diagnostic marker, the 
first 476 patients (age 58.1 ± 11.5 years; 61.7% female; 82.6% Caucasian) were grouped 
into a prediction rule training set and the final 126 patients (age 58.7 ± 9.22 years; 56.3% 
female; 85.7% Caucasian) were grouped into an independent validation set. There were no 
significant demographic differences between the training and validation set.
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The prediction rule was optimized using the training dataset with 343 healthy control 
patients vs. 31 patients with advanced adenomas. In the training set, the only significant 
demographic difference was an increase (P = 0.004) in the age of patients with advanced 
adenomas (63.4 ± 9.8 years) relative to control (57.3 ± 11.4 years). We subsequently 
validated the prediction rule using patients in the validation set with 68 healthy controls vs. 
8 patients with advanced adenomas and 7 patients with multiple non-advanced adenomas. 
There were no significant demographic differences between these three validation set patient 
groupings.
Optical alterations occurring in CRC field carcinogenesis
Combining the training and validation set, Fig. 3A and Fig. 3B show the alterations in the 
optical properties  and D, respectively. For  we observed a significant 38.3% decrease in 
value (P = 0.012) between controls and patients with advanced adenomas. There was no 
significant difference detected in  for patients with any number of non-advanced 
adenomas. For D, there was a progressive increase in value from control to 1 or 2 non-
advanced adenoma (P = 0.019) to multiple non-advanced adenoma (P = 0.017) and 
advanced adenoma patients (P = 0.002). The directionality of these changes (  and ) is 
consistent with trends observed in three prior studies of rectal mucosa in field 
carcinogenesis, corroborating the claim that the current study is detecting the same 
alterations that were previously observed ex-vivo (21-23).
Diagnostic Power of the LEBS Marker
The diagnostic LEBS marker was evaluated according to Eq. 1 as a linear combination of 
and D. As shown in Fig. 3C, the LEBS marker remains unaltered for patients with 1 or 2 
non-advanced adenomas, but shows a progressive increase in value for patients with 
multiple non-advanced adenomas (P = 0.052) and those with advanced adenomas (P = 
0.004). Figure 3D shows two receiver operating characteristic (ROC) curves generated using 
the LEBS marker values for patients harboring advanced adenomas and those with multiple 
non-advanced adenomas. The overall accuracy of detecting advanced adenomas 
(summarized as the area under the ROC curve) was favorable at 82%. Applying the optimal 
LEBS marker threshold to the validation set provided 88% sensitivity to advanced adenomas 
with 72% specificity. For multiple non-advanced adenomas, the diagnostic potential was 
moderately lower with 71% sensitivity and 73% overall accuracy. Table 1 summarizes the 
test performance characteristics of the LEBS marker for the validation dataset.
Potential Confounders
To assess the contribution of common CRC risk factors to our diagnostic results, we carried 
out an analysis of covariance (ANCOVA) with the LEBS marker as the dependent variable 
and the presence of advanced adenoma, endoscopist, age, gender, race, smoking history, 
alcohol history, and personal/family history of adenoma/cancer as predictors (results 
summarized in Table 2). After including these factors into our model, the LEBS marker 
remained a highly significant predictor of advanced adenomas with P<0.001. The 
contributions from all other confounding factors were insignificant except for gender.
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The influence of gender is attributed to significant differences between the genders for 
healthy controls, shown in Fig. 4A. At the same time, there are no significant gender 
differences for patients harboring advanced adenomas. Moreover, there remains a highly 
significant increase (P<0.001) in the LEBS marker from female controls to females with 
advanced adenomas and from male controls to males with advanced adenomas. We 
furthermore wanted to determine if the LEBS marker was confounded by benign 
hyperplastic polyps. Figure 4b shows no significant changes in the LEBS marker relative to 
control for patients with hyperplastic polyps (P = 0.66).
Influence of advanced adenoma location
We next wanted to assess whether the rectal LEBS marker was sensitive to advanced 
adenomas found throughout the colon. We therefore separated patients with advanced 
adenomas into two groups according to the colon location in which the largest polyp was 
found. Proximal adenomas were defined as lesions found within the first portion of the colon 
prior to the splenic flexure (e.g., lesions in the cecum, ascending colon, hepatic flexure, or 
transverse colon), while distal adenomas were defined as lesions found in the final portion of 
the colon (e.g., lesions in the splenic flexure, descending colon, sigmoid colon, or rectum). 
Figure 4C shows a highly significant increase in the LEBS marker (P<0.001) for all 
advanced adenomas, regardless of their position within the colon. There was no significant 
difference in the LEBS marker between patients with proximal and distal advanced 
adenomas.
Pilot Study of the LEBS marker in patients without colon preparation
Applying the model developed in the prepped training set to the smaller unprepped pilot 
study dataset shows a similar progressive increase in the LEBS marker for patients with 
increasing levels of dysplasia (shown in Fig. 4D). Relative to healthy controls, the LEBS 
marker is significantly increased (P = 0.04) for patients with advanced adenomas. At the 
same time, there are only insignificant differences measured for patients with non-advanced 
adenomas. Importantly, the values of the LEBS marker for healthy controls in this pilot 
study are consistent with both the training and validation datasets (i.e., there are non-
significant differences in value). Furthermore, a paired t-test on 7 patients who underwent 
LEBS measurement both with and without colon preparation showed insignificant 
differences between measurements (P = 0.18). Taken together, these results suggest that 
colon preparation may have a negligible effect on LEBS measurements. However, due to the 
limited sample size of this dataset, a larger study is needed to confirm these findings.
Discussion
In three previous studies of rectal biopsies (21-23), our group developed sophisticated 
optical instrumentations to establish the location and nature of the structural alterations 
occurring in CRC field carcinogenesis. The first study provided proof-of-principle for the 
diagnostic potential of rectal LEBS with an area under the ROC curve of 89.5% for patients 
harboring advanced adenomas (21). We next established that this diagnostic signal is the 
result of synergistic changes in the epithelial cells and surrounding stroma (i.e.,  and 
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in both compartments) (23). Armed with these observations ex-vivo, we developed the 
minimally invasive LEBS probe to optimally interrogate the alterations in-vivo (30).
In the current study, we confirmed that the trends observed ex-vivo were recapitulated in-
vivo. First, we observed a significant decrease in  and increase in D for patients harboring 
advanced adenoma. Importantly, the directionality of the changes was consistent with ex-
vivo findings (22). In order to form a single diagnostic marker, we combined  and D in a 
logistic regression to formulate the LEBS marker. The cross-validated LEBS marker was 
highly sensitive to clinically relevant adenomas with 88% sensitivity for advanced 
adenomas, 71% sensitivity to multiple non-advanced adenomas, and 72% specificity in the 
validation set. Moreover, after incorporating a number of CRC risk factors (e.g., 
endoscopist, age, gender, race, smoking/alcohol/cancer history) into an ANCOVA model, 
the LEBS marker remained highly predictive of the presence of advanced adenoma 
(P<0.001). Finally, we provided proof-of-principle for the operation of LEBS in patients 
without colon preparation.
From a mechanistic point of view, the changes in D provide fundamental insight into the 
changes in rectal mucosa morphology occurring in field carcinogenesis. Physically 
speaking, the observed increase in D indicates a shift in tissue ultra-structural composition 
towards larger features (i.e., small features aggregate to form larger structures). Although 
LEBS does not directly resolve the specific structures which contribute to this change, a 
number of different lines of evidence point to a synergistic combination of intracellular and 
extracellular components (17, 23). Within the nucleus of histologically normal human rectal 
cells, we previously observed an up-regulation in the histone deacetylase (HDAC) enzyme 
class responsible for enabling DNA to wrap more tightly around the histones (15). We 
subsequently confirmed that this change in gene expression resulted in an increase D using 
direct visual confirmation with transmission electron microscopy (38). In the extracellular 
tissue component the increase in D is likely a result of collagen fiber bundling and cross-
linking potentially induced by the up-regulation of lysyl-oxidase (LOX) or lysyl-oxidase like 
proteins (LOXL) (17, 23). One interesting observation about both of these structural changes 
is that they form a continuum with alterations typically associated with frank cancer. For 
example, chromatin compaction is a well-known marker of neoplasia that is commonly used 
in histopathology (39). However, whereas the changes in the later stages of cancer 
development occur at structural length-scales on the order of several microns, the changes in 
field carcinogenesis present themselves at ultra-structural length-scales on the order of tens 
to hundreds of nm.
From a clinical perspective, any viable CRC risk stratification method must be highly 
sensitive to premalignant advanced adenomas, support a high level of patient compliance, 
and unburden limited endoscopy capacity. With these goals in mind, the use of optical 
LEBS markers offers a number of attractive advantages for use in CRC pre-screening. First, 
is the high 88% sensitivity to advanced adenomas, which ensures that most patients who 
would benefit from colonoscopy screening are correctly identified. In comparison, other 
minimally invasive techniques such as fecal tests suffer from low test sensitivity to advanced 
adenomas (10.8%, 29.5%, and 42.4% sensitivity for FOBT (6, 7), FIT (7), and sDNA (4) 
respectively) – though overall program sensitivity is expected to increase when fecal tests 
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are applied on an annual basis. Furthermore, the LEBS probe combines a design that is 
straightforward to implement and minimally intrusive to the patient. Such a design could 
therefore be implemented in the primary care setting in order to boost theoretical patient 
compliance. Finally, given the baseline performance and prevalence observed in the current 
study, the theoretical one-time use of LEBS pre-screening would more than half the number 
of colonoscopies needed to identify one advanced adenoma from 16 down to 7. Such an 
outcome would result in a more efficient use of endoscopy resources.
There are a number of important limitations in the current study that should be 
acknowledged. First, is the modest 72% specificity compared with FOBT (95.2 % (6, 7)), 
FIT (97.3 % (7)), and sDNA (86.6 % (4)) – meaning that a large number of unnecessary 
colonoscopies would still be performed under a theoretical LEBS pre-screening program. 
Furthermore, we note that the rather high ~13% dropout rate for LEBS measurements based 
on rational marker exclusion criteria reduces the practical accuracy of a real-world LEBS 
test. With these two points in mind, we note that the current study presents data acquired 
with a first generation in-vivo LEBS instrument. Thus, the performance from this report 
should be viewed as the “floor” and underestimates the potential power of this approach in 
newer optimized design iterations.
Another limitation of the current study is that patients were enrolled through hospital 
locations with largely Caucasian demographics (83.4% in the current study). Although 
ANCOVA showed that the LEBS marker was not confounded by race, further clinical 
studies will need to draw from a more diverse demographic pool in order to more fully 
validate the viability of our approach. Next, the modest number of advanced adenomas 
(N=41) limits the precision with which test performance characteristics be determined. 
Furthermore, due to a non-zero colonoscopic miss rate (~1-2% for advanced adenomas and 
~15-25% for all adenomas) (40), there is the potential for patient misclassification. 
Similarly, patient classification was carried out according to size estimates from 
colonoscopy that may over- or under-state the actual size. Taken together, these limitations 
indicate that further clinical LEBS studies are still needed.
A further important limitation of the current study is that all patients in main study followed 
standard preparation protocols for colonoscopy, including colonic purge, prior to 
measurement with LEBS. To ensure optimal patient compliance, rectal LEBS analysis 
would need to be performed without the requirement of a colonic purge. Although we 
presented preliminary results demonstrating the potential of using rectal LEBS in patients 
without colon preparation, further studies are needed to fully assess the diagnostic potential 
of and patient compliance for such a procedure. Accordingly, the pilot unprepped should be 
viewed as a proof-of-principle for the operation of LEBS in patients without colonic purge.
In conclusion, we provide the first evidence that in-vivo LEBS analysis of the rectal mucosa 
is sensitive to clinically relevant premalignant lesions throughout the colon. We envision the 
future use of LEBS as the first step in a two-tiered approach for colorectal cancer screening. 
Under this approach, patients within the general screening population would undergo LEBS 
analysis during their annual physical exam. Those patients deemed to be at the highest risk 
of developing colorectal cancer would then proceed to a follow-up colonoscopy in order to 
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remove all precancerous adenomas via polypectomy. In order to move closer towards this 
goal, further studies of rectal LEBS applied to patients without colonic preparation are 
currently underway.
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Translational Relevance
Our multidisciplinary group identifies patients at risk of developing cancer through 
application of the well-established concept of field carcinogenesis - the idea that genetic/
epigenetic changes diffusely spread throughout an organ create a ‘fertile field’ from 
which frank cancer may develop. The implications of field carcinogenesis on cancer 
screening are twofold: First, it enables the early detection at a time-point where 
preventative measures are most effective. Second, since the field is spread throughout an 
organ, a patient's risk level can be assessed through easily accessible surrogate tissue 
sites. Low-coherence enhanced backscattering (LEBS) is a 3.4 mm diameter fiber-optic 
probe technology that detects the structural consequences of colorectal field 
carcinogenesis through in-vivo interrogation of the rectal mucosa. From a translational 
perspective, we envision the future use of LEBS applied in the primary care setting 
during an annual physical exam to identify those patients who would most benefit from a 
colonoscopy.
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Figure 1. 
Clinical LEBS probe and point-of-care instrumentation used for data collection. (A) Mobile 
point-of-care system housing the data acquisition instrumentation, calibration mechanism, 
and custom operating software. (B) Backscattering light spectrum measured by the LEBS 
probe at 3 collection angles: −0.6°, +0.6° & +1.12° relative to the incident direction. (C) 
Demonstration of the scale of the LEBS probe relative to the hand of a clinician. Rectal 
LEBS measurements are taken via direct insertion into the colon. (D) Schematic showing 
the 3.4 mm diameter fiber-optic LEBS probe. The inset shows an image of the linear optical 
fiber array, with sample illumination via one of two inner fibers and collection of 
backscattered light via the remaining fibers.
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Figure 2. 
Diagram and categorization of all enrolled patients. AA = patients with advanced adenomas 
and non-AA = patients with non-advanced adenomas.
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Figure 3. 
Optical alterations of the rectal mucosa in patients exhibiting CRC field carcinogenesis 
enables accurate detection of clinically relevant adenomas. (A) Shows a significant decrease 
in the reduced scattering coefficient  for patients harboring advanced adenomas. (B) 
Shows a significant increase in the mass density distribution factor D. (C) Shows the 
diagnostic LEBS marker for patients in the validation set. (D) Shows the receiver operating 
characteristic (ROC) curves for validation set patients. The area under the curve (AUC) is 
82% for advanced adenomas and 73% for multiple non-advanced adenomas. The x-axis of 
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panels A-C are ordered according to increasing aggressiveness from left to right. Control = 
healthy controls, Non-AA = patients with non-advanced adenomas, AA = patients with 
advanced adenomas.
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Figure 4. 
Diagnostic LEBS marker separated according to gender (panel A), other polyp types (panel 
B), and advanced adenoma location (panel C). (D) Diagnostic LEBS marker evaluated in 
patients without colonic preparation. In panel a, the P-values displayed below the LEBS 
marker for male and female patients harboring advanced adenoma are both calculated with 
respect to the corresponding gender of healthy control.
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Table 1
Validation Set Test Performance Characteristics
Adenoma Type Sensitivity Specificity AUC [95% CI]
Advanced Adenoma 88% [65%, 100%] 72% [61%, 83%] 82% [70%, 94%]
Multiple non-Advanced Adenomas 71% [37%, 100%] As above 73% [58%, 89%]
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Table 2
Confounding Factor Analysis
Factor P-value
Advanced Adenoma <0.001
Endoscopist 0.80
Age 0.95
Gender <0.001
Race 0.71
Smoking 0.94
Alcohol 0.96
Personal history of adenoma or colon cancer 0.13
Family history of adenoma or colon cancer 0.55
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